Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Marshall Austin

Showing results (11-20 of 104) with videos related to

Pageof 11
Sort By:
Journal of the American Society of Cytopathology|May 3, 2019
Increased cervical cancer risk associated with extended screening intervals after negative human papillomavirus test results: Bayesian risk estimates using the Pittsburgh Cervical Cancer Screening ModelR Marshall Austin, Agnieszka Onisko
Journal of the American Society of Cytopathology|May 3, 2019
Whose cervical screening model predictions will prove to be correct?R Marshall Austin, Amanda Herbert
American Journal of Clinical Pathology|March 30, 2020
What Constitutes Optimal Cervical Screening for Young Women Ages 21 to 29 Years?R Marshall Austin, Chenquan Zhao
Cancer Cytopathology|June 24, 2016
HPV test results provide useful risk stratification information in women with ASC-H Pap test findingsR Marshall Austin, Chengquan Zhao
Cytojournal|July 3, 2014
Is 58% sensitivity for detection of cervical intraepithelial neoplasia 3 and invasive cervical cancer optimal for cervical screening?R Marshall Austin, Chengquan Zhao
Gynecologic Oncology|September 15, 2007
Human papillomavirus DNA detection in ThinPrep Pap test vials is independent of cytologic sampling of the transformation zoneChengquan Zhao, R Marshall Austin
Cancer|May 20, 2008
Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sampleChengquan Zhao, R Marshall Austin
Drug, Healthcare and Patient Safety|November 16, 2012
Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screeningSonya Naryshkin, R Marshall Austin
Archives of Pathology & Laboratory Medicine|September 1, 2011
Unrecognized risks associated with new cervical screening guidelines for younger womenR Marshall Austin, Chengquan Zhao
American Journal of Clinical Pathology|April 29, 2016
Follow-up of Women With Negative Pap Test Results and Abnormal Clinical Signs or SymptomsRebecca Ocque, R Marshall Austin
Pageof 11

Showing results (11-20 of 104) with videos related to

Sort By:
Pageof 11
Journal of the American Society of Cytopathology|May 3, 2019
Increased cervical cancer risk associated with extended screening intervals after negative human papillomavirus test results: Bayesian risk estimates using the Pittsburgh Cervical Cancer Screening ModelR Marshall Austin, Agnieszka Onisko
Journal of the American Society of Cytopathology|May 3, 2019
Whose cervical screening model predictions will prove to be correct?R Marshall Austin, Amanda Herbert
American Journal of Clinical Pathology|March 30, 2020
What Constitutes Optimal Cervical Screening for Young Women Ages 21 to 29 Years?R Marshall Austin, Chenquan Zhao
Cancer Cytopathology|June 24, 2016
HPV test results provide useful risk stratification information in women with ASC-H Pap test findingsR Marshall Austin, Chengquan Zhao
Cytojournal|July 3, 2014
Is 58% sensitivity for detection of cervical intraepithelial neoplasia 3 and invasive cervical cancer optimal for cervical screening?R Marshall Austin, Chengquan Zhao
Gynecologic Oncology|September 15, 2007
Human papillomavirus DNA detection in ThinPrep Pap test vials is independent of cytologic sampling of the transformation zoneChengquan Zhao, R Marshall Austin
Cancer|May 20, 2008
Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sampleChengquan Zhao, R Marshall Austin
Drug, Healthcare and Patient Safety|November 16, 2012
Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screeningSonya Naryshkin, R Marshall Austin
Archives of Pathology & Laboratory Medicine|September 1, 2011
Unrecognized risks associated with new cervical screening guidelines for younger womenR Marshall Austin, Chengquan Zhao
American Journal of Clinical Pathology|April 29, 2016
Follow-up of Women With Negative Pap Test Results and Abnormal Clinical Signs or SymptomsRebecca Ocque, R Marshall Austin
Pageof 11